Details
Stereochemistry | ACHIRAL |
Molecular Formula | C13H19ClN2O2 |
Molecular Weight | 270.755 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCN(CC)CCOC(=O)C1=C(Cl)C=C(N)C=C1
InChI
InChIKey=VDANGULDQQJODZ-UHFFFAOYSA-N
InChI=1S/C13H19ClN2O2/c1-3-16(4-2)7-8-18-13(17)11-6-5-10(15)9-12(11)14/h5-6,9H,3-4,7-8,15H2,1-2H3
DescriptionCurator's Comment: description was created based on several sources, including
http://www.hmdb.ca/metabolites/HMDB15292 | https://www.drugbank.ca/drugs/DB01161
Curator's Comment: description was created based on several sources, including
http://www.hmdb.ca/metabolites/HMDB15292 | https://www.drugbank.ca/drugs/DB01161
Chloroprocaine (Nesacaine®, Nesacaine®-MPF) is a non pyrogenic local anesthetic. Nesacaine® is indicated for the production of local anesthesia by infiltration and peripheral nerve block. It is not to be used for lumbar or caudal epidural anesthesia. Nesacaine®-MPF is indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks. Nesacaine® and Nesacaine®-MPF are not to be used for subarachnoid administration. Chloroprocaine (Nesacaine®, Nesacaine®-MPF), like other local anesthetics, blocks the generation and the conduction of nerve impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse and by reducing the rate of rise of the action potential. It acts mainly by inhibiting sodium influx through voltage gated sodium channels in the neuronal cell membrane of peripheral nerves. When the influx of sodium is interrupted, an action potential cannot arise and signal conduction is thus inhibited.
Originator
Sources: https://www.google.com/patents/US2460139
Curator's Comment: Marks, H.C. and Rubin, M.I.; US. Patent 2,460,139; January 25,1949; assigned to Wallace&Tiernan Products, Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2096682 Sources: https://www.drugbank.ca/drugs/DB01161 |
208.0 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | NESACAINE Approved UseNesacaine 1% and 2% Injections, in multidose vials with methylparaben as preservative, are indicated for the production of local anesthesia by infiltration and peripheral nerve block. They are not to be used for lumbar or caudal epidural anesthesia. Nesacaine-MPF 2% and 3% Injections, in single dose vials without preservative and without EDTA, are indicated for the production of local anesthesia by infiltration, peripheral and central nerve block, including lumbar and caudal epidural blocks. Nesacaine and Nesacaine-MPF Injections are not to be used for subarachnoid administration. Launch Date1955 |
PubMed
Title | Date | PubMed |
---|---|---|
Persistent neurologic deficit and adhesive arachnoiditis following intrathecal 2-chloroprocaine injection. | 1980 Jun |
|
Prolonged neural blockade following regional analgesia with 2-chloroprocaine. | 1980 Jun |
|
Deaths from local anesthetic-induced convulsions in mice. | 1980 Jun |
|
Chloroprocaine neurotoxicity: four additional cases. | 1982 Feb |
|
Neurological toxicity of the subarachnoid infusion of bupivacaine, lignocaine or 2-chloroprocaine in the rat. | 1985 Apr |
|
Effects of cimetidine and ranitidine on local anesthetic central nervous system toxicity in mice. | 1986 Aug |
|
Recent advances in local anaesthesia. | 1986 May |
|
The role of 2-chloroprocaine and sodium bisulfite in rat sciatic nerve edema. | 1986 Sep |
|
Grand mal seizures after 2-chloroprocaine epidural anesthesia in a patient with plasma cholinesterase deficiency. | 1987 Jul |
|
Panic disorder following 2-chloroprocaine. | 1989 Jul |
|
Back pain following epidurally administered Nesacaine-MPF. | 1989 Jul |
|
Does chloroprocaine (Nesacaine MPF) for epidural anesthesia increase the incidence of backache? | 1989 Sep |
|
Treatment of nesacaine-MPF-induced back pain with calcium chloride. | 1990 Apr |
|
More on back pain after Nesacaine-MPF. | 1990 Nov |
|
Spinal anesthesia. | 2005 Oct |
|
Use of spinal anaesthesia in day surgery. | 2006 Dec |
|
Chloroprocaine may not affect epidural morphine for postcesarean delivery analgesia. | 2006 Feb |
|
Intrathecal 2-chloroprocaine for lower limb outpatient surgery: a prospective, randomized, double-blind, clinical evaluation. | 2006 Jul |
|
Spinal anesthesia with lidocaine or preservative-free 2-chlorprocaine for outpatient knee arthroscopy: a prospective, randomized, double-blind comparison. | 2007 Apr |
|
A study comparing chloroprocaine with lidocaine for skin infiltration before intravenous catheter insertion. | 2007 Aug |
|
Delayed-type hypersensitivity (type IV) reactions in dental anesthesia. | 2007 Jul-Aug |
|
Pain and efficacy of local anesthetics for central venous access. | 2008 |
|
Postdischarge complications and rehabilitation after ambulatory surgery. | 2008 Dec |
|
Lower-body warming mimics the normal epidural-induced reduction in the shivering threshold. | 2008 Jan |
|
Combined spinal and epidural anaesthesia with chloroprocaine for hysterectomy. | 2008 Jan |
|
Recurrent headache due to MS plaque. | 2008 Mar |
|
Spinal 2-chloroprocaine: effective dose for ambulatory surgery. | 2008 May |
|
A randomized, prospective, double-blind trial comparing 3% chloroprocaine followed by 0.5% bupivacaine to 2% lidocaine followed by 0.5% bupivacaine for interscalene brachial plexus block. | 2008 Nov |
|
Coming to a head. | 2008 Oct |
|
A survey of perioperative and postoperative anesthetic practices for cesarean delivery. | 2009 |
|
Corrected scoliosis, cholinesterase deficiency, and cesarean section: a case report. | 2009 |
|
Pseudocholinesterase enzyme deficiency: a case series and review of the literature. | 2009 Dec 4 |
|
A controlled clinical interventional trial comparing 2% chloroprocaine-bupivicaine versus 2% lidocaine-bupivicaine for retrobulbar anesthesia in scleral buckling surgery. | 2009 Feb |
|
Ultrasound improves the success rate of a sural nerve block at the ankle. | 2009 Jan-Feb |
|
The interaction between epidural 2-chloroprocaine and morphine: a randomized controlled trial of the effect of drug administration timing on the efficacy of morphine analgesia. | 2009 Jul |
|
Cytotoxicity of local anesthetics in human neuronal cells. | 2009 Mar |
|
Ultrasound improves the success rate of a tibial nerve block at the ankle. | 2009 May-Jun |
|
Bicarbonate plus epinephrine shortens the onset and prolongs the duration of sciatic block using chloroprocaine followed by bupivacaine in sprague-dawley rats. | 2009 May-Jun |
|
Complications and controversies of regional anaesthesia: a review. | 2009 Oct |
|
Prolonged neuromuscular blockade following succinylcholine administration to a patient with a reduced butyrylcholinesterase activity. | 2010 |
|
Selected Gamma Aminobutyric Acid (GABA) Esters may Provide Analgesia for Some Central Pain Conditions. | 2010 Aug 3 |
|
Advances in labor analgesia. | 2010 Aug 9 |
|
Effects of epidural fentanyl on speed and quality of block for emergency cesarean section in extending continuous epidural labor analgesia using ropivacaine and fentanyl. | 2010 Feb |
|
Acute pain management in children. | 2010 Jul 15 |
|
[Spinal anaesthesia in day case surgery--Old technique--new trends]. | 2010 Mar |
|
Vacuoles: a hollow threat? | 2010 Mar |
|
Ultrasound does not improve the success rate of a deep peroneal nerve block at the ankle. | 2010 Mar-Apr |
|
Sertraline-induced pseudocholinesterase enzyme deficiency. | 2010 Nov 16 |
|
Diabetic parturient - Anaesthetic implications. | 2010 Sep |
|
Diagnosis and management of pre-eclampsia: an update. | 2010 Sep 30 |
Patents
Sample Use Guides
Chloroprocaine may be administered as a single injection or continuously through an indwelling catheter. The smallest dose and concentration required to produce the desired result should be used. The maximum single recommended doses of chloroprocaine in adults are: without epinephrine, 11 mg/kg, not to exceed a maximum total dose of 800 mg; with epinephrine (1:200,000), 14 mg/kg, not to exceed a maximum total dose of 1000 mg.
Route of Administration:
Intravenous
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4005099
The study was instituted to examine the differential blocking activity of a series of amino-ester agents using an in vitro rabbit vagus nerve preparation. The ED50 (50% depression of the action potential amplitude) of the chloroprocaine hydrochloride were 0.17 mM, 0.20 mM and 0.23 mM for A, B and C fibres, respectively.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
||
|
NDF-RT |
N0000175976
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
||
|
WHO-ATC |
N01BA04
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
||
|
NDF-RT |
N0000166743
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
||
|
NDF-RT |
N0000175683
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
||
|
WHO-VATC |
QN01BA04
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
605
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
Chloroprocaine
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
3301
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
487
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
7145
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
133-16-4
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
8612
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
SUB06193MIG
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
m3430
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | Merck Index | ||
|
DB01161
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
DTXSID8022799
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
Chloroprocaine
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
C004616
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
100000081848
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
3636
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
5YVB0POT2H
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
5YVB0POT2H
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
20859
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | RxNorm | ||
|
C72168
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY | |||
|
CHEMBL1179047
Created by
admin on Fri Dec 15 15:45:27 GMT 2023 , Edited by admin on Fri Dec 15 15:45:27 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
METABOLITE (PARENT)
SALT/SOLVATE (PARENT)